Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
about
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaFifteen years of irinotecan therapy for pediatric sarcoma: where to next?Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic LandscapesTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyIrinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature.Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.Advances in paediatric cancer treatmentImmunotherapy in pediatric malignancies: current status and future perspectivesPreclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.Targeted therapy for soft tissue sarcomas in adolescents and young adults.The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Clinical research on rare diseases of children: neuroblastoma.Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties.Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group.Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?
P2860
Q26747666-59200AE7-81D6-47DB-97AF-D7DC64CD0431Q26795742-7FCAB42F-86D8-44C1-A59E-B167D1B4A5F3Q26801785-B18BF419-2E37-460A-9B95-D1014195FDFFQ26993238-A55FAFF2-E036-42F4-BBCE-AF01DA1D5037Q33417823-2698FE7D-5D9A-47A2-9BDA-558BADCEC92CQ33438641-B5733E04-B5C2-461F-A7EC-4A17178E25DCQ36508630-2BA6FF08-6EF4-48A8-9E35-EBA36FB693D4Q36691818-8E1C3D60-01D4-45BC-BF7B-4D39813E3054Q37256170-807BF0A5-8E48-4AE6-A403-82119DC4D5A5Q37742014-76C19D0E-9C74-414F-8CC0-84DAD37EBC58Q38252537-5997B3A5-824E-4DAF-BFDE-C822BC0C1553Q38791761-DC1F7FF8-AF96-4CAF-A20F-18CBC0EAA997Q41008169-7AD42D5D-6701-4A6B-9C68-655BEB8290C0Q41093026-88F0590C-7199-4073-A5E7-278EBA13E46AQ47101870-C3A70549-FBEF-4A3B-9869-996CA7AE765BQ48114539-101B117D-B99B-46E8-BDA5-D8F95223A2E8Q52901669-D31FF1CB-D111-4F7F-A580-A89CE44678C5
P2860
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Pilot study of vincristine, or ...... solid tumors or brain tumors.
@en
Pilot study of vincristine, or ...... solid tumors or brain tumors.
@nl
type
label
Pilot study of vincristine, or ...... solid tumors or brain tumors.
@en
Pilot study of vincristine, or ...... solid tumors or brain tumors.
@nl
prefLabel
Pilot study of vincristine, or ...... solid tumors or brain tumors.
@en
Pilot study of vincristine, or ...... solid tumors or brain tumors.
@nl
P2093
P2860
P356
P1476
Pilot study of vincristine, or ...... solid tumors or brain tumors.
@en
P2093
Brian Turpin
Brian Weiss
James Geller
Lars Wagner
Rajaram Nagarajan
Timothy Cripe
P2860
P304
P356
10.1002/PBC.24547
P577
2013-04-29T00:00:00Z